Lilly to supply 300,000 vials of COVID-19 monoclonal antibody to the U.S.
Eli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreRead the latest pharmaceutical industry press releases, news updates and articles on coronavirus COVID-19 medical treatment, therapies and drug and vaccine development.
Eli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read moreSYNLAB, leading European provider of medical diagnostic solutions, has revealed the successful authorization of saliva sampling platform, another groundbreaking non-invasive
Read moreNext-gen immunotherapy company BioNTech announced this month the completion of a share purchase agreement with Swiss pharma giant Novartis AG,
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreAt a time when pharma and biotech companies worldwide are racing to develop a vaccine, researchers at the University of
Read more